Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CDC25A | P30304 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
| ▸ | CDC25C | P30307 | 1/20 | 0.36 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.36 |
| ▸ | LATS1 | O95835 | 1/20 | 0.35 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22191096 | 0.82 | PSEN1 (0.52) | DYRK1APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2562421 | 0.80 | PSEN1 (0.40) | DYRK1APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12289961 | 0.76 | PDE3B (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12287887 | 0.74 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12287262 | 0.72 | MAPT (0.40) | DYRK1APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL14991117 | 0.72 | GRIA1 (0.38) | DYRK1APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12287625 | 0.72 | PSEN1 (0.36) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12289929 | 0.71 | KCNA5 (0.39) | DYRK1AMAPTGRIA1NPC1RAB9A | |
| SCHEMBL22191333 | 0.69 | AURKA (0.53) | DYRK1AMAPTMEN1KMT2AGAA | |
| SCHEMBL21170087 | 0.69 | PSEN1 (0.41) | DYRK1APSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3127541-B1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS INC (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20170281621-A1 | SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS | CYTOKINETICS INC (US) | 2017-10-05 | — | — | US | disclosed |
| US-9604965-B2 | Substituted pyridazines as skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| EP-3127541-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | Cytokinetics, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| EP-2563365-B1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20150322018-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | ASHCRAFT LUKE W (US) | 2015-11-12 | — | — | US | disclosed |
| US-8969346-B2 | Amino-pyridazine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130143862-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS, INC. | 2013-06-06 | — | — | US | disclosed |
| WO-2011133882-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281621-A1 | SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS | MUSK, PYGM, GYS1 | DYRK1A 1408/4885PSEN1 2563/4885PSEN2 3315/4885 |
| US-20130143862-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | SLC7A1, F12, C5 | DYRK1A 1366/4885PSEN1 1365/4885PSEN2 1728/4885 |
| US-20150322018-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | SLC7A1, F12, C5 | DYRK1A 1353/4885PSEN1 1351/4885PSEN2 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.